Summary
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study.
The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022.
The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer.
We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
FAQs
Our frequently questions
Find out how iliomad can help your company.
Only visible in production
Healthcare AI Agents, Vendor Breaches and GDPR Reforms: Weekly Privacy and Regulation Digest
This week's digest covers autonomous AI agent risks, a wave of US healthcare vendor breaches, the EU Digital Omnibus GDPR mandate and Swiss voice-biometric enforcement.
Clinical study protocol data protection: a practical guide for sponsors
Learn how to embed GDPR-compliant data protection into your clinical study protocol. Practical guidance on Section 13, DPIAs, transfers and local formalities.
Clinical Site Agreement: Navigating US Export Control Review of Cross-Border Data Transfers in Clinical Trials
Learn how institutional export control policies at clinical sites affect cross-border data transfers in trials, even below DOJ Bulk Data Rule thresholds.
